Atogepant (Qulipta) vs Erenumab (Aimovig)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Atogepant (Qulipta)

Marketed by AbbVie

Approved in Migrainesmall molecule
Reliable signal

NCT03777059 · Phase 3 · completed

The study was randomized, double-blind, and placebo-controlled, with 910 participants and a clinically meaningful primary endpoint based on change in monthly migraine days. The primary comparison was statistically significant in favor of atogepant for 10 mg, 30 mg, and 60 mg doses, each with p<0.0001.

Next expected readout: March 2028 · NCT05711394 (registry estimate)

Reported efficacy

Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) (met)

Result source: NCT03777059

Erenumab (Aimovig)

Marketed by Amgen and partners

Approved in Migrainemonoclonal antibody
Reliable signal

NCT02456740 · Phase 3 · completed

The trial randomly assigned 955 participants to erenumab 70 mg, erenumab 140 mg, or placebo and used quadruple blinding during the 24-week placebo-controlled phase. The clinical primary endpoint, change in monthly migraine days, was significantly better with both erenumab doses than with placebo.

Next expected readout: July 2031 · NCT07655440 (registry estimate)

Reported efficacy

Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) (met)

Result source: NCT03867201

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Atogepant (Qulipta)
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) NCT03777059 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33) NCT02848326 · Phase 2/3 · design grade: strong · reviewed ClinicalTrials.gov result
Erenumab (Aimovig)
Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) NCT02456740 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine days (last 4 of 12 weeks): erenumab 70 mg -6.64 and 140 mg -6.63 vs placebo -4.18; differences -2.46 (95% CI -3.52 to -1.39) and -2.45 (95% CI -3.51 to -1.38), both p<0.001 (CT.gov posted results). NCT02066415 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase): Placebo -1.84 migraine days / month (Standard Error 0.21) | Erenumab 70 mg QM -2.88 migraine days / month (Standard Error 0.21) NCT02483585 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT03867201 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atogepant (Qulipta)'s landscape · Erenumab (Aimovig)'s landscape